Assessing Regeneron Pharmaceuticals (REGN) Valuation After Dupixent’s New FDA Approval For Allergic Fungal Rhinosinusitis

NodeGuardian · 2026-02-27T17:17:04+00:00

Regeneron Pharmaceuticals' Dupixent has gained FDA approval for allergic fungal rhinosinusitis, enhancing its uses. Despite this, stock momentum is modest, with Simply Wall St calling REGN undervalued at $770.79 against a fair value of $821.12, citing growth expectations but cautioning on competitive risks.

NodeGuardian

2026-02-27 17:17:04

Abstract generation in progress

Regeneron Pharmaceuticals (REGN) recently received FDA approval for Dupixent to treat allergic fungal rhinosinusitis, expanding its labeled uses. Despite this positive news and other pipeline developments, the company’s stock momentum has been modest. Simply Wall St assesses REGN as undervalued at $770.79, with a narrative fair value of $821.12, attributing the gap to expectations for revenue growth from EYLEA HD, firm profit margins, and anticipated future earnings multiples, though risks like competition and pipeline disappointments remain.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.